Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Common Equity: 2013-2025

Historic Common Equity for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $87.8 million.

  • Coherus Oncology's Common Equity rose 199.77% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 199.77%. This contributed to the annual value of -$132.0 million for FY2024, which is 31.76% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Common Equity is $87.8 million, which was down 26.75% from $119.8 million recorded in Q2 2025.
  • Coherus Oncology's Common Equity's 5-year high stood at $156.2 million during Q2 2021, with a 5-year trough of -$196.5 million in Q1 2023.
  • Moreover, its 3-year median value for Common Equity was -$132.0 million (2024), whereas its average is -$96.4 million.
  • As far as peak fluctuations go, Coherus Oncology's Common Equity crashed by 1,664.17% in 2023, and later skyrocketed by 242.47% in 2025.
  • Coherus Oncology's Common Equity (Quarterly) stood at $97.7 million in 2021, then plummeted by 240.62% to -$137.4 million in 2022, then crashed by 40.76% to -$193.4 million in 2023, then surged by 31.76% to -$132.0 million in 2024, then surged by 199.77% to $87.8 million in 2025.
  • Its last three reported values are $87.8 million in Q3 2025, $119.8 million for Q2 2025, and -$183.5 million during Q1 2025.